Patents Examined by Brad Duffy
  • Production of heteromultimeric proteins
    Patent number: 9637557
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: May 2, 2017
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Christoph Spiess, Daniel G. Yansura
  • pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
    Patent number: 9636374
    Abstract: Polymeric delivery systems for boronic acid-containing therapeutics, related compounds and methods of use, for a pH-sensitive chemoselective approach to delivery of such a therapeutic.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 2, 2017
    Assignee: Northwestern University
    Inventors: Phillip B. Messersmith, Jing Su, Vincent L. Cryns
  • Antibodies that specifically bind to TIM3
    Patent number: 9631026
    Abstract: Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: April 25, 2017
    Assignee: Cellerant Therapeutics, Inc.
    Inventors: Holger Karsunky, Ying-Ping Jiang
  • Reagent for diagnosing tumor, pharmaceutical composition, and screening method
    Patent number: 9632092
    Abstract: The present invention provides antibodies useful for diagnosing and treating tumors as well as methods of screening for antitumor agents. More specifically, tumors can be diagnosed and treated using an anti-phosphorylated p62 antibody that recognizes phosphorylation of serine at position 351 of an amino acid sequence of SEQ ID No. 1 or at a position corresponding thereto. An antitumor agent can be obtained by screening for a substance that inhibits the phosphorylation or that dephosphorylates the phosphorylated serine.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: April 25, 2017
    Assignee: Tokyo Metropolitan Institute of Medical Science
    Inventors: Masaaki Komatsu, Yoshinobu Ichimura
  • Polymalic acid-based nanobiopolymer compositions
    Patent number: 9623041
    Abstract: Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (?-L-malic acid) PMLA covalently linked to molecular modules that include morpholino antisense oligonucleotides (AONa), an siRNA or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: April 18, 2017
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Satoshi Inoue, Hui Ding, Eggehard Holler, Keith L. Black, Julia Y. Ljubimova
  • Anti-HER3 antibodies and uses thereof
    Patent number: 9611331
    Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: April 4, 2017
    Assignee: Roche Glycart AG
    Inventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
  • Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents
    Patent number: 9610249
    Abstract: Methods for determining dosage of HER2-targeted anthracycline-containing immunoliposomes are disclosed, as are methods of treating cancer patients with HER2-positive tumors using dosages so determined. Upon administration, the dosages share the low cardiotoxicity profile of standard dosages of non-immunoliposomal (untargeted), anthracycline-containing liposomes.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: April 4, 2017
    Assignee: Merrimack Pharmaceuticals. Inc.
    Inventors: Joseph G. Reynolds, Kenneth J. Olivier, Jr., Bart S. Hendriks, Thomas Wickham, Stephan Klinz, Elena Geretti
  • Globo H and related anti-cancer vaccines with novel glycolipid adjuvants
    Patent number: 9603913
    Abstract: An immunogenic composition containing a glycan conjugate including a carrier protein, and a glycan including Globo H, an immunogenic fragment thereof, or stage-specific embryonic antigen-4 (SSEA-4), wherein the glycan is conjugated with the carrier protein through a linker.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: March 28, 2017
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu, Alice L. Yu, John Yu
  • Hybridoma cell line G250 and its use for producing monoclonal antibodies
    Patent number: 9605075
    Abstract: This invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: March 28, 2017
    Assignee: WILEX AG
    Inventors: Egbert Oosterwijk, Sven Warnaar, Stefan Ullrich
  • Methods for generating radioimmunoconjugates
    Patent number: 9603954
    Abstract: Methods for generating an Ac-225 radioconjugate comprising a monoclonal antibody (mAb) (IgG) is disclosed. The Ac-225 radioimmunoconjugate is an [Ac-225]-p-SCN-Bn-DOT AIHuM195 radioimmunoconjugate.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: March 28, 2017
    Assignee: ACTINIUM PHARMACEUTICALS INC.
    Inventors: Jaime Simon, A. Gaylord King, Josue Manuel Moreno Bermudez
  • Antigen binding formats for use in therapeutic treatments or diagnostic assays
    Patent number: 9598499
    Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: March 21, 2017
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, ASSISTANCE PUBLIQUE—HOPITAUX DE MARSEILLE
    Inventors: Daniel Baty, Patrick Chames, Martine Mansais, Brigitte Kerfelec, Caroline Rozan
  • Antibodies and immunoconjugates and uses therefor
    Patent number: 9593167
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 14, 2017
    Assignee: GENENTECH, INC.
    Inventors: Mark S. Dennis, Bonnee Rubinfeld, Paul Polakis, Aya Jakobovits
  • Recombinant monovalent antibodies
    Patent number: 9587023
    Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: March 7, 2017
    Assignees: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
  • IgE antibodies for the inhibition of tumor metastasis
    Patent number: 9587032
    Abstract: The present invention provides novel IgE antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: March 7, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Joseph A. Mollick, Pearline Teo, Paul J. Utz
  • Biodegradable particulate formulations
    Patent number: 9572894
    Abstract: The present invention provides three-component compositions comprising microparticles, a tumor antigen, a first immune adjuvant, and a second immune adjuvant. Also provided are chemo-immunotherapeutic compositions comprising microparticles, a chemotherapeutic agent, and an immune adjuvant.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: February 21, 2017
    Assignee: The University of Iowa Research Foundation
    Inventors: Aliasger K. Salem, Sean M. Geary, George J. Weiner, Caitlin Lemke, Yogita Krishnamachari
  • Internalizing human monoclonal antibodies targeting prostate and other cancer cells
    Patent number: 9567402
    Abstract: In various embodiments various cancer specific antibodies and immunoconjugates are provided. In certain embodiments the antibodies specifically bind and are internalized into a prostate cancer cell, where the antibodies specifically binds cells that express or overexpress a CD46, and where the antibodies specifically bind sushi domain 1 of said CD46 (CD46 CPP1).
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: February 14, 2017
    Assignee: The Regents of the University of California
    Inventor: Bin Liu
  • Recombinant anti-MUC1 antibodies
    Patent number: 9546217
    Abstract: Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: January 17, 2017
    Assignee: MAB FACTORY GMBH
    Inventors: Christian Behrens, Holger Thie, Michael Hust, Lars Toleikis, Thomas Schirrmann, Stefan Dübel, Christophe De Romeuf
  • Fusion antibodies
    Patent number: 9541547
    Abstract: The present invention provides novel antibodies. In particular, the present invention provides fusion antibodies comprising antibody heavy and light chain fusions. The present invention further provides multivalent antibodies comprising multiple fusion antibody chains. The present invention further provides methods of generating splice resistant antibody genes.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: January 10, 2017
    Assignee: CATALENT PHARMA SOLUTIONS, INC.
    Inventors: Gregory T. Bleck, Dona York, Ian Collins
  • Human FGF receptor and ?-Klotho binding proteins
    Patent number: 9517264
    Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to ?-Klotho, or ?-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: December 13, 2016
    Assignee: AMGEN INC.
    Inventors: Roger Fachini, Ian Foltz, Seog Joon Han, Susie Miki Harris, Shaw-Fen Sylvia Hu, Chadwick Terence King, Yang Li, Ji Lu, Mark Leo Michaels, Jeonghoon Sun
  • Anti-HER2 antibodies and immunoconjugates
    Patent number: 9518118
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski